BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...

IQVIA conducted a thorough ... Integrating the patient journey Failures in patient engagement and retention can delay or stop a clinical trial. DCT studies are proving to be helpful with this ...

IQVIA introduced a suite of clinical technology solutions that can speed clinical trials while reducing burden on patients, and also empower the company to utilize data more strategically.

RESEARCH TRIANGLE PARK, N.C., January 13, 2025--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research ... regulatory compliance, and patient safety.